Publications by authors named "Carol J Wikstrand"

Claim this Profile
C
Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy.
Vidyalakshmi Chandramohan, Xuhui Bao, Stephen T Keir, Charles N Pegram, Scott E Szafranski, Carol J Wikstrand

Clin Cancer Res· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors.
Michael R Zalutsky, Abraham Boskovitz, Chien-Tsun Kuan, Charles N Pegram, Joanne Ayriss, Carol J Wikstrand

Nucl Med Biol· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MRP3: a molecular target for human glioblastoma multiforme immunotherapy.
Chien-Tsun Kuan, Kenji Wakiya, James E Herndon, Eric S Lipp, Charles N Pegram, Carol J Wikstrand

BMC Cancer· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Convection enhanced delivery of boronated EGF as a molecular targeting agent for neutron capture therapy of brain tumors.
Weilian Yang, Rolf F Barth, Gong Wu, Tianyao Huo, Werner Tjarks, Carol J Wikstrand

J Neurooncol· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of amino-terminal extracellular domain of somatostatin receptor 2 by specific monoclonal antibodies and quantification of receptor density in medulloblastoma.
Chien-Tsun Kuan, Carol J Wikstrand, Roger E McLendon, Michael R Zalutsky, Ujendra Kumar

Hybridoma (Larchmt)· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies.
Weilian Yang, Gong Wu, Rolf F Barth, Michele R Swindall, Achintya K Bandyopadhyaya, Carol J Wikstrand

Clin Cancer Res· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
John C Sok, Francesca M Coppelli, Sufi M Thomas, Miriam N Lango, Sichuan Xi, Carol J Wikstrand

Clin Cancer Res· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular targeting and treatment of EGFRvIII-positive gliomas using boronated monoclonal antibody L8A4.
Weilian Yang, Rolf F Barth, Gong Wu, Shinji Kawabata, Thomas J Sferra, Carol J Wikstrand

Clin Cancer Res· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme.
Chien-Tsun Kuan, Kenji Wakiya, Jeannette M Dowell, James E Herndon, David A Reardon, Carol J Wikstrand

Clin Cancer Res· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tenascin and microvessel stromal changes in patients with non-Hodgkin's lymphoma are isolated to the sites of disease and vary in correlation to disease activity.
David A Rizzieri, Martha Wadleigh, Carol J Wikstrand, Karen P Mann, Filiz Sen

Leuk Lymphoma· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.
Ranjit K Goudar, Qing Shi, Mark D Hjelmeland, Stephen T Keir, Roger E McLendon, Carol J Wikstrand

Mol Cancer Ther· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a syngeneic rat brain tumor model expressing EGFRvIII and its use for molecular targeting studies with monoclonal antibody L8A4.
Weilian Yang, Rolf F Barth, Gong Wu, Michael J Ciesielski, Robert A Fenstermaker, Carol J Wikstrand

Clin Cancer Res· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune responses of breast cancer patients to mutated epidermal growth factor receptor (EGF-RvIII, Delta EGF-R, and de2-7 EGF-R).
Enkhtsetseg Purev, Dewei Cai, Eric Miller, Rolf Swoboda, Ted Mayer, Carol J Wikstrand

J Immunol· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monoclonal antibodies for brain tumour treatment.
Abraham Boskovitz, Carol J Wikstrand, Chien-Tsun Kuan, Michael R Zalutsky, David A Reardon

Expert Opin Biol Ther· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Poliovirus receptor CD155-targeted oncolysis of glioma.
Melinda K Merrill, Guenter Bernhardt, John H Sampson, Carol J Wikstrand, Darell D Bigner

Neuro Oncol· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.
Chris A Learn, Tristan L Hartzell, Carol J Wikstrand, Gary E Archer, Jeremy N Rich

Clin Cancer Res· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of gefitinib in recurrent glioblastoma.
Jeremy N Rich, David A Reardon, Terry Peery, Jeannette M Dowell, Jennifer A Quinn, Carol J Wikstrand

J Clin Oncol· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors.
Amy B Heimberger, Laura E Crotty, Gary E Archer, Kenneth R Hess, Carol J Wikstrand

Clin Cancer Res· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.
David A Reardon, Gamal Akabani, R Edward Coleman, Allan H Friedman, Henry S Friedman, Carol J Wikstrand

J Clin Oncol· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system.
Carol J Wikstrand, Vanessa R Cole, Laura E Crotty, John H Sampson, Darell D Bigner

Cancer Immunol Immunother· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis